ovarian cancer

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

News

Ovarian cancer data restores faith in Corcept's relacorilant

After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

News

Dr Dominik Schumacher, Tubulis' co-founder and chief executive

Germany's Tubulis raises €308m for ADC pipeline

Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.

Oncology

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

US and UK flags meet on a diagonal, with grey border line

AbbVie joins BMS in taking a hard line on UK drug pricing

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.

New hope for ovarian cancer, with Alexander Schneider

Ovarian cancer data restores faith in Corcept's relacorilant

Germany's Tubulis raises €308m for ADC pipeline

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

Ignota vacuums up Kronos Bio's drug programmes

AbbVie joins BMS in taking a hard line on UK drug pricing

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

ovarian cancer

Editor's Picks